Case Study: Olmesartan Medoxomil: A Prodrug of Olmesartan
Olmesartan is a durable, specific, and competitive nonpeptide angiotensin II receptor antagonist used to treat hypertension. To achieve better oral bioavailability its ester prodrug, olmesartan medoxomil, was developed. Olmesartan medoxomil is suitable for once daily oral administration and is available in tablet form.
KeywordsOlmesartan Medoxomil Antihypertensive Efficacy Ambulatory Blood Pressure Measurement Ester Prodrug Daily Oral Administration
Unable to display preview. Download preview PDF.
- Ball KJ, Williams PA, and Stumpe KO. Relative Efficacy of an Angiotensin II Antagonist Compared with Other Antihypertensive Agents. Olmesartan Medoxomil versus Antihypertensives. J Hypertens 2001; 19Suppl 1:S49–56Google Scholar
- Kobayashi N, Fujimori I, Watanabe M, and Ikeda T. Real-time Monitoring of Metabolic Reactions by Microdialysis in Combination with Tandem Mass Spectrometry: Hydrolysis of CS-866 In Vitro in Human and Rat Plasma, Livers, and Small Intestines. Anal Biochem 2000; 287:272–278PubMedCrossRefGoogle Scholar
- Laeis P, Puchler K, and Kirch W. The Pharmacokinetic and Metabolic Profile of Olmesartan Medoxomil limits the Risk of Clinically Relevant Drug Interaction. J Hypertens 2001;19Suppl 1:S21–32Google Scholar
- Puechler K, Laeis P, and Stumpe K. Blood Pressure Response, but no Adverse Event Incidence, Correlates with Dose of Angiotensin II Antagonist. J Hypertens 2001; 19Suppl 1:S41–48Google Scholar
- Song JC, and White M. Olmesartan Medoxomil (CS-866). An Angiotensin II Receptor Blocker for Treatment of Hypertension. Formulary 2001; 36:487–499Google Scholar
- von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho LR, and Gonzalez L. Olmesartan Medoxomil: Influence of Age, Renal and Hepatic Function on the Pharmacokinetics of Olmesartan Medoxomil. J Hypertens 2001; 19Suppl 1:S33–40Google Scholar
- Yanagisawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, Sada T, Mizuno M, Ikeda M, Miyamoto S, Furukawa Y, and Koike H. Nonpeptide Angiotensin II Receptor Antagonists: Synthesis, Biological Activities, and Structure-activity Relationships of Imidazole-5-carboxylic Acids Bearing Alkyl, Alkenyl, and Hydroxyalkyl Substituents at the 4-position and their Related Compounds. J Med Chem 1996; 39:323–338PubMedCrossRefGoogle Scholar